Loading stock data…
OnKure Therapeutics (OKUR)
$4.12-0.10 (-2.37%)
Market ClosedLast close Jul 24
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OnKure Therapeutics, Inc. in the Healthcare sector is trading at $4.12 with a market capitalization of $165M. Wall Street consensus targets $19.50 (4 analysts), implying a +373.3% move over the next 12 months. The stock is currently 23% below its 52-week high of $5.38, remaining 16.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +373.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$15.62M↓ | -$14.13M↑ | -$15.50M↑ | -$16.32M↑ | -$17.00M |
| Net Income | -$15.16M↓ | -$13.50M↑ | -$14.70M↑ | -$15.39M↑ | -$15.93M |
Peer Comparison
JNJUNHPFE
Fundamentals
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-2...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$165.42M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.87%
Volume
Today's trading volume
181,996
Recent News
OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near
OnKure Therapeutics (NASDAQ:OKUR) used a scientific webcast to outline its strategy for developing mutant-selective PI3Kα inhibitors, emphasizing allosteric inhibition as a potential way to improve efficacy and tolerability in cancer and vascular anomalies. Nick Saccomano, president and chief execu
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
Thermo Fisher heads into Q1 earnings with Life Sciences Solutions growth in focus, as bioproduction strength and new innovations may drive results.
Promising Penny Stocks To Watch In December 2025
As the Federal Reserve's meeting unfolds, investors are closely monitoring potential interest rate cuts that could influence market dynamics. Amid these developments, penny stocks continue to capture attention as a viable investment area, despite their seemingly outdated label. These smaller or newer companies can offer unique opportunities for growth and value, especially when they demonstrate strong financial resilience.
3 Promising Penny Stocks With Market Caps Under $200M
As the U.S. stock market shows signs of resilience with major indices like the Nasdaq and S&P 500 posting gains, investors are increasingly looking for opportunities beyond the usual tech giants. Penny stocks, a term that might seem outdated, still represent a compelling investment area by offering access to smaller or newer companies at lower price points. When these stocks are supported by strong financials and solid fundamentals, they can provide potential growth opportunities without many...
Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky
NasdaqGM:OKUR 1 Year Share Price vs Fair Value Explore OnKure Therapeutics's Fair Values from the Community and select...